Clinical recognition and management of patients exposed to biological warfare agents

JAMA

Volumn 278, Issue 5, 1997, Pages 399-411

  Franz, David R ^a,c   Jahrling, Peter B ^a   Friedlander, Arthur M ^a   McClain, David J ^a   Hoover, David L ^b   Bryne, W Russell ^a   Pavlin, Julie A ^a   Christopher, George W ^a   Eitzen, Edward M ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTITOXIN; ANTIVIRUS AGENT; BOTULINUM TOXIN; CHLORAMPHENICOL; CIDOFOVIR; CIPROFLOXACIN; DOXYCYCLINE; GENTAMICIN; IMMUNOGLOBULIN; PENICILLIN G; RIBAVIRIN; STAPHYLOCOCCUS ENTEROTOXIN B; STREPTOMYCIN; TETRACYCLINE;

ANTHRAX; ARTICLE; BIOLOGICAL WARFARE; BOTULISM; BRUCELLOSIS; HEMORRHAGIC FEVER; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PLAGUE; PRIORITY JOURNAL; Q FEVER; SMALLPOX; STAPHYLOCOCCUS INFECTION; TULAREMIA; VIRUS ENCEPHALITIS;

EID: 0030851442     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.278.5.399     Document Type: Article

References (146)

1. Health Aspects of Chemical and Biological Weapons: Report of a WHO Group of Consultants. Geneva, Switzerland: World Health Organization; 1970:72,99.
2. Turnbull PCB, ed. Proceedings of the international workshop on anthrax. Salisbury Med Bull Suppl. 1996;87:1-139.
3. Brachman PS, Friedlander AM. Anthrax. In: Plotkin SA, Mortimer EA Jr, eds. Vaccines. Philadelphia, Pa: WB Saunders Co; 1994:729-739.
4. Meselson M, Guillemin J, Hugh-Jones M, et al. The Sverdlovsk anthrax outbreak of 1979. Science. 1994;266:1202-1208.
5. Dutz W, Kohout E. Anthrax. Pathol Annu. 1971; 6:209-248.
6. Friedlander AM. Anthrax. In: Zajtchuk R, ed. Textbook of Military Medicine: Medical Aspects of Chemical and Biological Warfare. Washington, DC: US Dept of the Army, Surgeon General, and the Borden Institute; 1997:467-478.
7. BrachmanPS. Inhalation anthrax. Ann NY Acad Sci. 1980;353:83-93.
8. Abramova FA, Grinberg LM, Yampolskaya OV, et al. Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc Natl Acad Sci USA. 1993;90:2291-2294.
9. Friedlander AM, Welkos SL, Pitt MLM, et al. Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis. 1993;167:1239-1243.
10. Grimont F, Verger JM, Cornelis P, et al. Molecular typing of Brucella with cloned DNA probes. Res Microbiol 1992;143:55-65.
11. Olle GJ, Canela SJ. An outbreak of Brucella melitensis infection by airborne transmission among laboratory workers. Am J Public Health. 1987;77:335-338.
12. Franz DR, Parrott CD, Takafuji ET. The US biological warfare and biological defense programs. In: Zajtchuk R, ed. Textbook of Military Medicine: Medical Aspects of Chemical and Biological Warfare. Washington, DC: US Dept of the Army, Surgeon General, and the Borden Institute; 1997:425-436.
13. Mousa AM, Elhag KM, Khogali M, Sugathan TN. Brucellosis in Kuwait. Trans R Soc Trop Med Hyg. 1987;81:1020-1021.
14. Young EJ. An overview of human brucellosis. Clin Infect Dis. 1995;1:283-289.
15. Mousa AR, Elhag KM, Khogali M, Marafie AA. The nature of human brucellosis in Kuwait: study of 379 cases. Rev Infect Dis. 1988;10:211-217.
16. Gotuzzo E, Alarcon GS, Bocanegra TS, et al. Articular involvement in human brucellosis. Semin Arthritis Rheum. 1982;12:245-255.
17. Mousa AR, Muhtaseb SA, Almudallal DS, Khodeir SM, Marafie AA. Osteoarticular complications of brucellosis. Rev Infect Dis. 1987;9:531-543.
18. Ariza J, Gudiol F, Valverde J, et al. Brucellar spondylitis. Rev Infect Dis. 1985;7:656-664.
19. Ibrahim AIA, Shetty SD, Saad M, Bilal NE. Genito-urinary complications of brucellosis. Br J Urol. 1988;61:294-298.
20. Peery TM, Belter LF. Brucellosis and heart disease. Am J Pathol. 1960;36:673-697.
21. Evans AC. Comments on the early history of human brucellosis. In: Larson CH, Soule MH, eds. Brucellosis. Baltimore, Md: Waverly Press; 1950:1-8.
22. Crosby E, Llosa L, Miro QM, Carrillo C, Gotuzzo E. Hematologic changes in brucellosis. J Infect Dis. 1984;150:419-424.
23. Young EJ. Serologic diagnosis of human brucellosis: analysis of 214 cases by agglutination tests and review of the literature. Rev Infect Dis. 1991;13:359-372.
24. Gotuzzo E, Carrillo C, Guerra J, Llosa L. An evaluation of diagnostic methods for brucellosis. J Infect Dis. 1986;153:122-125.
25. Moyer NP, Holcomb LA. Brucella. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RF, eds. Manual of Clinical Microbiology. 6th ed. Washington, DC: ASM Press; 1995:549-555.
26. Luzzi GA, Brindle R, Sockett PN, Solera J, Klenerman P, Warrell DA. Brucellosis. Trans R Soc Trop Med Hyg. 1993;87:138-141.
27. Joint FAO/WHO expert committee on brucellosis. World Health Organ Tech Rep Ser. 1986;740: 1-132.
28. Chan R, Hardiman RP. Endocarditis caused by Brucella melitensis. Med J Aust. 1993;158:631-632.
29. Butler T. Plague and Other Yersinia Infections. New York, NY: Plenum Press; 1983.
30. McGovern TW, Friedlander AM. Plague. In: Zajtchuk R, ed. Textbook of Military Medicine: Medical Aspects of Chemical and Biological Warfare. Washington, DC: US Dept of the Army, Surgeon General, and the Borden Institute; 1997:479-502.
31. Perry RD, Fetherson JD. Yersinia pestis. Clin Microbiol Rev. 1997;10:35-66.
32. Russell P, Eley SM, Bell DL, Manchee RJ, Titball RW. Doxycyeline or ciprofloxacin prophylaxis and therapy against Yersinia pestis infection in mice. J Antimicrob Chemother. 1996;37:769-774.
33. Cavanaugh DC, Cadigan FC, Williams JE, Marshall JD. General medicine and infectious diseases. In: Ognibene AJ, Barrett ON, eds. Internal Medicine in Vietnam. Washington, DC: Office of the Surgeon General and Center of Military History; 1982.
34. Cavanaugh DC, Elisberg BL, Llewellyn CH, et al. Plague immunization. J Infect Dis. 1974;129:S37-S40.
35. Tigertt WD, Benenson AS. Studies on Q fever in man. Trans Assoc Am Physcians. 1956;69:98-104.
36. Marrie TJ, Langille D, Papukna V, Yates L. Truckin' pneumonia: an outbreak of Q fever in a truck repair plant. Epidemiol Infect. 1989;102:119-127.
37. Salmon MM, Howells B, Glencross EJG, et al. Q fever in an urban area. Lancet. 1982;1:1002-1004.
38. Smith DL, Ayres JG, Blair I, et al. A large Q fever outbreak in the West Midlands: clinical aspects. Respir Med. 1993;87:509-516.
39. Spicer AJ. Military significance of Q fever: a review. J R Soc Med. 1978;71:762-767.
40. Ferrante MA and Dolan MJ. Q fever meningoencephalitis in a soldier returning from the Persian Gulf War. Clin Infect Dis. 1993;16:489-496.
41. US Army Activity on the US Biological Warfare Programs. Vol II. February 24,1977. Unclassified document; L-3,4,5,6.
42. Raoult D, Marrie TJ. State-of-the-art clinical lecture: Q fever. Clin Infect Dis. 1995;20:489-496.
43. Derrick EH. The course of infection with Coxiella burnetii. Med J Aust. 1973;1:1051-1057.
44. Dupuis G, Petite J, Olivier P, Vouilloz M. An important outbreak of human Q fever in a Swiss alpine valley. Int J Epidemiol. 1987;16:282-287.
45. Brouqui PB, Dupont HT, Drancourt M, et al. Chronic Q fever. Arch Intern Med. 1993;153:643-648.
46. Uhaa IJ, Fishbein DB, Olson JG, et al. Evaluation of specificity of indirect enzyme-linked immunosorbent assay for diagnosis of human Q fever. J Clin Microbiol. 1994;32:1560-1565.
47. Waag D, Chulay J, Marrie T, England M, Willaims J. Validation of an enzyme immunoassay for serodiagnosis of acute Q fever. Eur J Clin Microbiol Infect Dis. 1995;14:421-427.
48. Raoult, D. Treatment of Q fever. Antimicrob Agents Chemother. 1993;37:1733-1736.
49. Marmion BP, Ormsbee RA, Kyrkor M. Vaccine prophylaxis of abattoir-associated Q fever. Epidemiol Infect. 1990;104:275-287.
50. Acklund JR, Worswick DA, Marmion BP. Vaccine prophylaxis of Q fever. Med J Aust. 1994; 160: 704-708.
51. Benenson AS. Q fever vaccine. In: Smadel JE, ed. Symposium on Q Fever by the Committee on Rickettsial Diseases. Washington, DC: Armed Forces Epidemiology Board; 1959:47-60.
52. Bell JF, Lackman DB, Meis A, Hadlow WJ. Recurrent reaction at site of Q fever vaccination in a sensitized person. Mil Med. 1964;124:591-595.
53. Lackman DB, Bell EJ, Bell JF, Pickens EG. Intradermal sensitivity testing in man with a purified vaccine for Q fever. Am J Public Health. 1962;52: 87-93.
54. Evans ME, Friedlander AM. Tularemia. In: Zajtchuk R, ed. Textbook of Military Medicine: Medical Aspects of Chemical and Biological Warfare. Washington, DC: US Dept of the Army, The Surgeon General, and the Borden Institute; 1997:503-512.
55. Evans ME, Gregory DW, Schaffner W, McGee ZA. Tularemia. Medicine. 1985;64:251-269.
56. McCrumb FR Jr. Aerosol infection of man with Pasteurella tularensis. Bacteriol Rev. 1961;25:262-267.
57. Miller RP, Bates JH. Pleuropulmonary tularemia. Am Rev Respir Dis. 1969;99:31-41.
58. Penn RL. Francisella tularensis (tularemia). In: Mandell GA, Bennett JE, Dolen R, eds. Principles and Practice of Infectious Diseases. New York, NY: Churchill Livingstone Inc; 1995:2060-2078.
59. Sawyer WD, Dangerfield HG, Hogge AL, Crozier D. Antibiotic prophylaxis and therapy of airborne tularemia. Bacteriol Rev. 1966;30:542-548.
60. Burke DS. Immunization against tularemia. J Infect Dis. 1977;135:55-60.
61. Arita I. Virological evidence for the success of the smallpox eradication programme. Nature. 1979; 279:293-298.
62. Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID. Smallpox and Its Eradication. Geneva, Switzerland: World Health Organization; 1988:1341.
63. Horgan ES, Ali Haseeb M. Cross immunity experiments in monkey between variola, alastrim, and vaccinia. J Hyg. 1939;39:615-637.
64. Report of the Investigation Into the Cause of the 1978 Birmingham Smallpox Occurrence. London, England: Her Majesty's Stationery Office; 1980.
65. Harper GJ. Airborne microorganisms. J Hyg. 1961;59:479-486.
66. Downie AW, St Vincent L, Meiklejohn G, et al. Studies on the virus content of mouth washings in the acute phase of smallpox. Bull World Health Organ. 1961;25:49-53.
67. Sarkar JK, Mitra AC, Mukherjee MK, De SK, Mazumdar DG. Virus excretion in smallpox. Bull World Health Organ. 1973;48:517-522.
68. Mitra AC, Sarkar JK, Mukherjee MK. Virus content of smallpox scabs. Bull World Health Organ. 1974;51:106-107.
69. Zdenek J. Human Monkeypox. Basel, Switzerland: S Karger; 1988.
70. Jezek Z, Fenner F. Human monkeypox. Virol Monogr. 1988;17:93-95.
71. Human monkeypox - Kasai Oriental, Zaire. MMWR Morb Mortal Wkly Rep. 1997;46:304-307.
72. Sarkar JK, Mitra AC, Mukherjee MK, De SK. Virus excretion in smallpox. Bull World Health Organ. 1973;48:523-527.
73. Kato S, Takahashi M, Kameyama S, Kamehora J. A study on the morphological and cyto-immunological relationship between the inclusions of variola, cowpox, rabbitpox, vaccinia (variola origin) and vaccinia IHD and consideration of the term 'Guarneri body.' Biken J. 1959;2;353-363.
74. Ibrahim MS, Esposito JJ, Jarhling PB, Lofts RS. The potential of 5 nuclease PCR for detecting a single-base polymorphism in orthopoxvirus. Mol Cell Probes. 1997;11:143-147.
75. Meikeljohn G, Kempe CH, Downie AW, Berge TO, St Vincent L, Rao AR. Air sampling to recover variola virus in the environment of a smallpox hospital. Bull World Health Organ. 1961;25:63-67.
76. Downie AW, Meiklejohn M, St Vincent L, Rao AR, Sundara Babu BV, Kempe CH. The recovery of smallpox from patients and their environment in a smallpox hospital. Bull World Health Organ. 1965; 33:615-622.
77. Wehrle PF, Posch J, Richter KH, et al. An airborne outbreak of smallpox in a German hospital and its significance with respect to other recent outbreaks in Europe. Bull World Health Organ. 1970; 43:669-679.
78. MacCallum FO, McDonald JR. Survival of variola virus in raw cotton. Bull World Health Organ. 1957;16:247-254.
79. Bauer DJ, St Vincent L, Kempe CH, Downie AW. Prophylactic treatment of smallpox contacts with N-methylisatin -thiosemicarbazone (compound 33T57, Marboran). Lancet. 1963;2:494-496.
80. de Valle LAR, de Melo PR, de Salles Gomes LF, Proença LM. Methisazone in prevention of variola minor among contacts. Lancet. 1965;2:976-978.
81. Bauer DJ, St Vincent L, Kempe CH, Young PA, Downie AW. Prophylaxis of smallpox with methisazone. Am J Epidemiol. 1969;90:130-145.
82. Rao AR, McKendrick GDW, Velayudhan L, Kamalakshi K. Assessment of an isothiazole thiosemicarbazone in the prophylaxis of contacts of variola major. Lancet. 1966;1:1072-1074.
83. Dixon CW. Smallpox. London, England: J & A Churchill; 1962.
84. Henderson DA. Smallpox. In: Maxcy-Rosenau; Sartwell PE, ed. Preventive Medicine and Public Health. 10th ed. New York, NY: Appleton Century-Crofts; 1973:104-116.
85. Huxsoll DL, Patrick WC, Parrott CD. Veterinary services in biological disasters. J Am Vet Med Assoc. 1987;190:714-722.
86. Richmond JY, McKinney RW. Biosafety in Microbiological and Biomedical Laboratories. Washington, DC: US Dept of Health and Human Services; 1993. HHS publication CDC 93-8395.
87. Davis NL, Powell N, Greenwald GF, et al. Attenuating mutations in the E2 glycoprotein gene of Venezuelan equine encephalitis virus. Virology. 1991;183:20-31.
88. Karabatsos N. International Catalogue of Arboviruses Including Certain Other Viruses of Vertebrates. 3rd ed. San Antonio, Tex: American Society for Tropical Medicine and Hygiene; 1985.
89. Johnson KM, Martin DH. Venezuelan equine encephalitis. Adv Vet Sci Comp Med. 1974;18:79.
90. Franck PT, Johnson KM. An outbreak of Venezuelan encephalitis in man in the Panama Canal Zone. Am J Trop Med Hyg. 1970;19:860-863.
91. Martin DH, Eddy GA, Sudia WD, Reeves WC, Newhouse VF, Johnson KM. An epidemiologic study of Venezuelan equine encephalomyelitis in Costa Rica, 1970. Am J Epidemiol. 1972;95:2565-2578.
92. Leon CA, Jaramillo R, Martinez S, et al. Sequelae of Venezuelan equine encephalitis in humans: a four-year follow-up. Int J Epidemiol. 1975;4:131-140.
93. Hart KL, Keen D, Belle EA. An outbreak of eastern equine encephalomyelitis in Jamaica, West Indies, Nov-Dec 1962, I: description of human cases. Am J Trop Med Hyg. 1964;13:331-334.
94. Clarke DH. Two non-fatal human infections with the virus of eastern encephalitis. Am J Trop Med Hyg. 1961;10:67-70.
95. Deresiewicz RL, Thaler SJ, Hsu L, Zamani AA. Clinical and neuroradiographic manifestations of Eastern equine encephalitis. N Engl J Med. 1997;336: 1867-1874.
96. Feemster RF. Equine encephalitis in Massachusetts. N Engl J Med. 1958;257:107-113.
97. Goldfield M, Welsh JN, Taylor BF. The 1959 outbreak of eastern encephalitis in New Jersey. Am J Epidemiol. 1968;87:32-38.
98. Hayes RO. Eastern and western encephalitis. In: Beran GW, ed. Handbook Series in Zoonoses: Viral Zoonoses, I. Boca Raton, Fla: CRC Press; 1981:29-57.
99. Briceño Rossi AL. Rural epidemic encephalitis in Venezuela caused by a group A arbovirus (VEE). In: Melnick JL, ed. Progress in Medical Virology, IX. Basel, Switzerland: S Karger AG; 1967:176-203.
100. Briceño Rossi AL. The frequency of VEE virus in the pharyngeal material of clinical cases of encephalitis. Gac Med Caracas. 1964;72:5-22.
101. Hinman AR, McGowan JE, Henderson BE. Venezuelan equine encephalomyelitis. Am J Epidemiol. 1971;93:130-136.
102. Calisher CH, Karabatsos N. Arbovirus serogroups: definition and geographic distribution. In: Monath TP, ed. The Arboviruses: Epidemiology and Ecology, I. Boca Raton, Fla: CRC Press; 1988:19-57.
103. Calisher CH, El-Kafrawi AO, Al-Deen Mahmud MI, et al. Complex specific immunoglobulin M antibody patterns in humans infected with alphaviruses. J Clin Microbiol. 1986;23:155-159.
104. Gold H, Hampil B. Equine encephalomyelitis in a laboratory technician with recovery. Ann Intern Med. 1942;16:556-569.
105. Hunt AR, Roerhig JT. Biochemical and biological characteristics of epitopes on the E1 glycoprotein of Western equine encephalitis virus. Virology. 1985;142:334-346.
106. Mathews JH, Roehrig JT. Determination of the protective epitopes on the glycoproteins of Venezuelan equine encephalomyelitis virus by passive transfer of monoclonal antibodies. J Immunol. 1982; 129:2763-2767.
107. McKinney RW, Berge TO, Sawyer WD, Tigertt WD, Crozier D. Use of an attenuated strain of Venezuelan equine encephalomyelitis virus for immunization in man. Am J Trop Med Hyg. 1963;12: 597-603.
108. McCormick JB, Webb PA, Krebs JW, Johnson KM, Smith E. A prospective study of epidemiology and ecology of Lassa fever. J Infect Dis. 1987;155: 437-444.
109. Maiztegui J, Feuillade M, Briggiler A. Progressive extension of the endemic area and changing incidence of Argentine hemorrhagic fever. Med Microbiol Immunol. 1986;175:149-152.
110. Johnson KM, Wiebenga NH, Mackenzie RB, et al. Virus isolations from human cases of hemorrhagic fever in Bolivia. Proc Soc Exp Biol Med. 1965;155: 113-118.
111. Salas R, De Manzione N, Tesh RB, et al. Venezuelan haemorrhagic fever. Lancet. 1991;338:1033-1036.
112. Coimbra TLM, Nassar ES, Burattini MN, et al. New arenavirus isolated in Brazil. Lancet. 1994;343: 391-392.
113. Easterday BC. Rift Valley fever. Adv Vet Sci. 1965;10:65-127.
114. van Eeden PJ, van Eeden SF, Joubert JR, King JB, van de Wal BW, Michell WL. A nosocomial outbreak of Crimean-Congo haemorrhagic fever at Tygerberg Hospital. S Afr Med J. 1985;68:718-721.
115. Lee HW. Hemorrhagic fever with renal syndrome in Korea. Rev Infect Dis. 1989;11:S864-S876.
116. Butler JC, Peters CJ. Hantaviruses and hantavirus pulmonary syndrome. Clin J Infect Dis. 1994;19:387-395.
117. Martini GA, Siegert R, eds. Marburg Virus Disease. New York, NY: Springer-Verlag NY Inc; 1971.
118. World Health Organization/International Study Team. Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ. 1978;56:271-293.
119. World Health Organization/International Study Team. Ebola haemorrhagic fever in Sudan, 1976. Bull World Health Organ. 1978;56:247-270.
120. Monath TP. Yellow fever: epidemics and research in the last forty years and prospects for the future. Am J Trop Med Hyg. 1991;45:1-43.
121. Peters CJ, Johnson ED, McKee KT. Filoviruses and management of viral hemorrhagic fever. In: Belshe RB, ed. Textbook of Human Virology. 2nd ed. St Louis, Mo: Mosby-Year Book Inc; 1991: 699-712.
122. Jahrling PB. Filoviruses and arenaviruses. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of Clinical Microbiology. 6th ed., Washington, DC: ASM Press; 1995:1068-1081.
123. Canonico PG, Kende M, Luscri BJ, et al. In-vivo activity of antivirals against exotic RNA viral infections. J Antimicrob Chemother. 1984;14(suppl) :27-41
124. McCormick JB, King IJ, Webb PA, et al. Lassa fever: effective therapy with ribavirin. N Engl J Med. 1986;314:20-26.
125. Huggins JW. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev Infect Dis. 1989;11:S750-S761.
126. Centers for Disease Control. Management of patients with suspected viral hemorrhagic fever. MMWR Morb Mortal Wkly Rep. 1988;37(suppl): 1-16.
127. Enria D, Maiztegui JI. Antiviral treatment of Argentine Hemorrhagic Fever. Antiviral Res. 1994;23:23-31.
128. Enria DA, Fernandez NJ, Briggiler AM, et al. Importance of neutralizing antibodies in treatment of Argentine haemorrhagic fever with immune plasma. Lancet. 1984;4:255-256.
129. Jahrling PB, Frame JD, Rhoderick JB, Monson MH. Endemic Lassa fever in Liberia. Trans R Soc Trop Med Hyg. 1985;79:380-384.
130. Shepherd AJ, Swanepoel R, Leman PA. Antibody response in Crimean-Congo hemorrhagic fever. Rev Infect Dis. 1989;11:S801-S806.
131. Jahrling PB, Geisbert J, Swearengen JR, et al. Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch Virol. 1996;(suppl 11):135-140.
132. Cochrane RC. Biological warfare research in the United States. In: History of the Chemical Warfare Service in World War II, VoI II. Frederick, Md: Historical Section, Plans, Training and Intelligence Division, Office of Chief, Chemical Corps, US Dept of the Army; 1947.
133. Gill DM. Bacterial toxins: a table of lethal amounts. Microbiol Rev. March 1982:86-94.
134. Simpson LL. Peripheral actions of the botulinum toxins. In: Simpson LL, ed. Botulinum Neurotoxin and Tetanus Toxin. New York, NY: Academic Press Inc; 1989:153-178.
135. Franz DR, Pitt LM, Clayton MA, Hanes MA, Rose KJ. Efficacy of prophylactic and therapeutic administration of antitoxin for inhalation botulism. In: Das Gupta B, ed. Botulinum and Tetanus Neurotoxins and Biomedical Aspects. New York, NY: Plenum Press; 1993:473-476.
136. Middlebrook JL. Contributions of the US Army to botulinum toxin research. In: Das Gupta B, ed. Botulinum and Tetanus Neurotoxins and Biomedical Aspects. New York, NY: Plenum Press; 1993:515-519.
137. Beneson AS. Control of Communicable Diseases in Man. 15th ed. Washington, DC: American Public Health Association; 1990:61-66.
138. Fraser JD. High-affinity binding of staphylococcal enterotoxins A and B to HLA-DR. Nature. 1989;339:221-223.
139. Mollick JA, Cook RG, Rich RR. Class II MHC molecules are specific receptors for staphylococcal enterotoxin A. Science. 1989;244:817-820.
140. Kappler J, Kotzin B, Herron L, et. al. Vβ-specific stimulation of human T cells by staphylococcal toxins. Science. 1989;244:811-813.
141. Stiles BG, Bavari S, Krakauer T, Ulrich RG. Toxicity of staphylococcal enterotoxins potentiated by lipopolysaccharide. Infect Immun. 1993;61:5333-5338.
142. Bavari S, Olson MA, Ulrich RG. Engineered bacterial superantigen vaccines. In: Brown F, Norrby E, Burton D, Mekalanos J. Vaccines 96. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1996:135-141.
143. Ulrich RG, Sidell S, Taylor TJ, Wilhelmsen CL, Franz DR. Staphylococcal enterotoxin B and related pyrogenic toxins. In: Zajtchuk R, ed. Textbook of Military Medicine: Medical Aspects of Chemical and Biological Warfare. Washington, DC: US Dept of the Army, The Surgeon General, and the Borden Institute; 1997:621-630.
144. Department of the Army, the Navy, and the Air Force. NATO Handbook on the Medical Aspects of NBC Defensive Operations. Washington, DC: Depts of the Army, Navy, and Air Force; February 1996.
145. Eickhoff TC. Airborne disease. Am J Epidemiol. 1996;144:S39-S46.
146. Last J, Wallace R, Barrett-Connor E, eds. Public Health and Preventive Medicine. 13th ed. East Norwalk, Conn: Appleton & Lange; 1992.